Navigation Links
Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
Date:11/17/2010

BASKING RIDGE, N.J., Nov. 17, 2010 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven L. Zelenkofske, D.O., F.A.C.C., Senior Vice President and Chief Medical Officer, and Chris Rusconi, Ph.D., Senior Vice President and Chief Scientific Officer, presented a poster about REG3 at the AHA Scientific Sessions meeting on November 17, 2010 at 9:30 a.m. CST in Chicago, IL.  

The poster, entitled "Discovery of a Novel Aptamer-Based Inhibitor of GPVI and its Matched Active Control Agent," illustrates the use of Regado's proprietary technology platform to identify a novel aptamer-control agent pair targeting GPVI. GPVI, which mediates collagen-induced platelet activation, is a novel target for a new antiplatelet agent.  High levels of GPVI are associated with the onset of multiple diseases, including diabetes, ACS, peripheral vascular disease and stroke.  

REG3, Regado's third development program, represents the first identification of an actively controllable GPVI antagonist and the first anti-platelet agent capable of providing active control of the duration and intensity of anti-platelet therapy.  IND-enabling studies are ongoing and first-in-human clinical studies are anticipated to begin in 2011.

The poster is coauthored by Christopher P. Rusconi, Ph.D., Juliana M. Layzer, Brian G. Stell, Sanjoy K. Mahanty, Ryan J. Quick, Tadeusz K. Wyrzykiewicz, Ph.D., Douglas G. Brooks, Ph.D. and Steven L. Zelenkofske, D.O., F.A.C.C., all from Regado Biosciences.

ABOUT REGADO BIOSCIENCESRegado Biosciences, Inc. is a private biopharmaceutical company pioneering a new therapeutic technology with the creation and development of proprietary controllable aptamer drug systems.  Each system comprises a nuclease-stabilized RNA aptamer, the therapeutic effect of which can be reversed partially or completely in real time
'/>"/>

SOURCE Regado Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
2. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
3. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
4. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Regado Biosciences Completes Patient Enrollment for Phase IIa Study of REG1 Anticoagulation System
7. Regado Biosciences Releases Positive Phase 2a Data for the Reversible Anticoagulant System REG1 at the European Society of Cardiology Congress In Barcelona, Spain
8. Regado Biosciences to Present at the Ninth Annual Joint Symposium of BioNJ and Pennsylvania Bio on November 17, 2009
9. Regado Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference on December 1, 2009
10. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... -- QT Vascular Ltd., together with its subsidiaries ("QT Vascular" ... design, assembly and distribution of advanced therapeutic solutions for ... into an agreement with a group of investors (the ... This funding will strengthen the Group,s working capital which ... Dr. Eitan Konstantino , Ph.D., ...
(Date:7/27/2015)... York , July 27, 2015 ... Research "Bionics Market - Global Industry Analysis, Size, Share, Growth, ... valued at USD 7.96 billion in 2014, growing at a ... USD 20.49 billion in 2021. The global bionics ... number of accidents, which is leading to paralysis or amputation ...
(Date:7/27/2015)... , July 27, 2015 Dynatronics Corporation (NASDAQ: DYNT ... Solaris therapeutic modality products. This approval allows the company to sell ... countries around the world. "Receiving the CE Mark represents ... stated Kelvyn H. Cullimore Jr. , president and CEO of ... network into China , Japan ...
Breaking Medicine Technology:QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 2QT Vascular Obtains Funding To Boost Growth Through Issuance of up to US$13.14 Million Convertible Bonds 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 2Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 3Global Bionics Market is Expected to Reach USD 20.49 Billion in 2021, Growing at CAGR of 13.2% From 2015 to 2021: Transparency Market Research 4Dynatronics Awarded CE Mark Approval for Its Solaris Products 2
... trauma or,noise-induced hearing loss. By any name, it,s the ... 28 million Americans,have impaired hearing; for as many as ... December 2007 issue of Harvard Men,s,Health Watch., Acoustic ... exposure,is the most common cause, but recreational noise -- ...
... Proven to Significantly Improve Overall Survival in ... Patients ... 19 ,Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX) today ... a supplemental New Drug Application for Nexavar(R) (sorafenib),tablets for the ...
Cached Medicine Technology:Your Hearing May be at Risk, Says Harvard Men's Health Watch 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 2Nexavar First FDA-Approved Drug Therapy for Liver Cancer 3Nexavar First FDA-Approved Drug Therapy for Liver Cancer 4Nexavar First FDA-Approved Drug Therapy for Liver Cancer 5Nexavar First FDA-Approved Drug Therapy for Liver Cancer 6
(Date:7/27/2015)... ... ... Throughout its 20 year history, Doctors on Liens has pioneered ... basis. As the personal injury and medical industries have changed, Doctors on Liens ... pain management physicians, to psychologists and more. And while many of these offices ...
(Date:7/27/2015)... ... July 27, 2015 , ... Recently, 10 Best Water ... respected water brands also made the organization’s list. As its name clearly indicates, 10 ... available. Here is a description of the top three brands, along with a listing ...
(Date:7/27/2015)... Dallas, Texas (PRWEB) , ... July 27, 2015 ... ... the use of fullerenes in medical and diagnostics applications is rapidly increasing and ... drug delivery and cancer treatment, they are increasingly being evaluated for use in ...
(Date:7/27/2015)... ... , ... Boston IVF, the first Massachusetts egg freezing center to assist in ... Nantucket Island for women who wish to learn more about their fertility and egg ... Chins Way, Nantucket Island 02554 from 4:30-6:30pm. , This casual and informative event will ...
(Date:7/27/2015)... ... 27, 2015 , ... Standifer Insurance Group, a locally owned insurance company with ... Conquest, a specialized camp for young people who have been hospitalized in the burn ... and four night curriculum designed to give burn survivors between the ages of 6-17 ...
Breaking Medicine News(10 mins):Health News:Doctors on Liens Adds Highly Respected Physical Therapy Office in Los Angeles 2Health News:Best Water Brand Awards Presented by 10 Best Water 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 2Health News:Fullerene Market to Grow at 13% CAGR to 2019 Says a New Research Report at Sandlerresearch.org 3Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 2Health News:Boston IVF to Host Egg Freezing Event in Nantucket on August 6th at 4:30pm 3Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 2Health News:Standifer Insurance Group and Camp Conquest Plan Joint Charity Initiative to Assist Hospitalized Children Suffering from Burn Injuries 3
... -- A common form of heart trouble called diastolic ... an increased risk of heart failure, new research shows. ... age, the heart,s left ventricle fills with blood in an ... The new study included more than 2,000 people aged ...
... HealthDay Reporter , TUESDAY, Aug. 23 (HealthDay News) -- ... regular medications for chronic conditions during their stay and ... say. Patients treated in the intensive care unit ... medication schedule after discharge, probably because there are so ...
... chemicals can be like putting together a puzzle. University ... the pieces together to more efficiently build complex molecules, ... by chemistry professor Martin Burke, the team published its ... Angewandte Chemie . Burke,s group is known for ...
... researchers have proposed in a new study a different ... using data from other similar chemicals. For ... have enough information to understand all of the effects ... this, the European Union enacted the REACH regulation, which ...
... patients treated at a U.S. military hospital in Afghanistan ... in the September issue of Infection Control and ... Healthcare Epidemiology of America. The findings underscore the need ... both soldiers and local patients are treated, the study,s ...
... -- The amount of fighting and arguing in your marriage ... study suggests. Ohio State University researchers looked at data ... 2000. Based on how often participants said they disagreed with ... high-conflict marriages. There was little change in any of ...
Cached Medicine News:Health News:Common Heart Dysfunction Can Help Bring on Heart Failure 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 2Health News:Mainstay Meds Often Cut Off Accidentally After Hospital Stay 3Health News:A new set of building blocks for simple synthesis of complex molecules 2Health News:Scientists develop new approaches to predict the environmental safety of chemicals 2Health News:Study: Afghan patients a common source of drug-resistant bacteria 2Health News:Couples Who Don't Fight Much Aren't Likely to Start 2
... Richmond Products includes the four demonstration plates, the ... for a total of 24 plates. Each of ... and clean page selection. The test also includes ... laminated copy of the score sheet. The score ...
... charts are recognized internationally as a ... deficiency. With normal color perception, the ... visible. Each color test plate in ... printed to measure incrementally higher color ...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Accepted by leading authorities as a simple and accurate method for discovering congenital color blindness of two type total color blindness and red/green blindness. This book is used for children an...
Medicine Products: